Skip to main content

SPR

Stock
Industrials
Aerospace & Defense

Performance overview

SPR Price
Price Chart

Forward-looking statistics

Beta
1.10
Risk
32.78%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005, and the firm is the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue.

Company info

SectorIndustrials
IndustryAerospace & Defense
Employees15K
Market cap$3.5B

Fundamentals

Enterprise value$9.7B
Revenue$6.1B
Revenue per employee
Profit margin-34.81%
Debt to equity-1.69

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$18.22
Dividend per share
Revenue per share$52.37
Avg trading volume (30 day)$48M
Avg trading volume (10 day)$66M
Put-call ratio

Macro factor sensitivity

Growth+5.7
Credit+1.7
Liquidity-3.5
Inflation+0.8
Commodities+0.5
Interest Rates-2.6

Valuation

Dividend yield0.00%
PEG Ratio49.03
Price to sales0.74
P/E Ratio49.03
Enterprise Value to Revenue1.57
Price to book-1.42

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend daySeptember 9, 2022

News

Space ETFs That Can Launch Your Portfolio Higher

The S&P Kensho Space Index's 51.99% surge underscores investor enthusiasm as defense, tourism and climate tech fuel the booming space economy.

Zacks Investment Research (July 18, 2025)
What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'

ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Investment Research (July 15, 2025)
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Zacks Investment Research (July 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free